

Adagrasib KRYSTAL-1

## PRELIMINARY SCORE

### CURATIVE



### NON-CURATIVE



## ADJUSTMENTS

### Quality of life



### Serious and disabling adverse effects



More serious and disabling adverse events observed



### Other adjustments



Adagrasib KRYSTAL-1

## FINAL SCORE

### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

### INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: Indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy

Experimental Arm: Adagrasib

Control Arm: Single arm



